No retraction, correction or concern found when last checked on Oct 21, 2026.
Evaluation of the Microbial Diversity in Amyotrophic Lateral Sclerosis Using High-Throughput Sequencing
Xin Fang, Xin Wang, Shaoguo Yang and 4 more
Frontiers in Microbiology · 2016
Abstract
More and more evidences indicate that diseases of the central nervous system (CNS) have been seriously affected by faecal microbes. However, little work is done to explore interaction between amyotrophic lateral sclerosis (ALS) and faecal microbes. In the present study, high-throughput sequencing method was used to compare the intestinal microbial diversity of healthy people and ALS patients. The principal coordinate analysis (PCoA), Venn and unweighted pair-group method using arithmetic averages (UPGMA) showed an obvious microbial changes between healthy people (group H) and ALS patients (group A), and the average ratios of Bacteroides, Faecalibacterium, Anaerostipes, Prevotella, Escherichia and Lachnospira at genus level between ALS patients and healthy people were 0.78, 2.18, 3.41, 0.35, 0.79 and 13.07. Furthermore, the decreased Firmicutes/Bacteroidetes ratio at phylum level using LEfSE (LDA >4.0), together with the significant increased genus Dorea (harmful microorganisms ) and significant reduced genus Oscillibacter, Anaerostipes, Lachnospiraceae (beneficial microorganisms) in ALS patients, indicated that the imbalance in intestinal microflora constitution had a strong association with the pathogenesis of ALS.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
Amyotrophic lateral sclerosis (ALS) belongs to idiopathic, fatal neurodegenerative disease of the human motor system, characterized by the loss of neurons at all levels of the motor system—from the cortex to the anterior horn of the spinal cord. The scientific and clinical interest in ALS is growing since the 1990s, and survival in ALS is now understood to be dependent on clinical presentation (phenotype), rate of disease progression, early presence of respiratory failure, and the nutritional status of patients. Unfortunately, less than 50% of patients can survive within 3 years of onset.
The human gastrointestinal tract is home to bacterial communities, and the microbes have profound implications on human metabolism, immunity and the gut-brain axis, and numerous studies have highlighted interactions between the central nervous system (CNS) and the gastrointestinal system. The brain may modulate peripheral gut functions to modify the gastrointestinal composition via releasing gut factors (hormones, neurotransmitters, immune factors), and the gut microbes, on the other hand, interact with the CNS by releasing of neurotransmitters, e.g., nitric oxide (NO, a major neurotransmitter in the brain) and g-aminobutyric acid (GABA, neurotransmitter produced Lactobacillus and Bifidobacterium). Short-chain fatty acids (SCFAs), the specific metabolites generated by gut bacteria, can cross the blood–brain barrier and its levels in the feces could be correlated negatively or positively with autism spectrum disorders (ASD). Moreover, researchers found that lipopolysaccharide (LPS), a constituent of Gram-negative bacteria markedly affected vagal afferent neuron function, with reduced vagal afferent leptin signaling.
Intestinal barrier dysfunction may promote the passage of toxins in the intestinal lumen into the blood, and the innate immune response and increased circulating LPS play pivotal roles in the pathogenesis of ALS. Furthermore, reduced tight junction proteins in the lumbar spinal cord, as well as the disruption of tissue barriers (the blood–spinal cord barrier and the blood–brain barrier) were identified both in ALS patients and animal models. However, the interaction of the gut microbiota with the ALS has not been investigated.
In the past, only a small fraction of all bacteria have been isolated and characterized severely limited by available technology and the shortage of reference genomes, and recent technological advances in next generation sequencing technology has enabled elucidation of the pleiotropic effects of microorganisms on the human host. In the present study, the high-throughput sequencing analyses were used to assess the interaction of the gut microbiota and the ALS, which proves basic data for the prevention and treatment of ALS.
Ethical Statement and Patients
The study was approved by the Ethical Committee of The First Affiliated Hospital of Nanchang University, all participants provided written informed consent and all the methods were carried out in accordance with the approved guidelines.
Six consecutive patients with ALS (according to the revised El Escorial criteria) were recruited at The First Affiliated Hospital of Nanchang University between 07/2015 and 05/2016, and patients who were unable to communicate, either verbally or by writing, were excluded. None had additional neurological disease or previous mental illness. Respiratory function measured by forced vital capacity (FVC) was above 70% and there was no evidence of nocturnal hypoventilation (Supplementary Table S1). Five healthy people without ALS were recruited as control. All people with random diets donated their first fecal motion of the day for only one time and the samples were stored at -70°C.
Extraction of Genomic DNA and High-Throughput Sequencing
Genomic DNA from each sample was extracted using a TIANamp Genomic DNA kit (TIANGEN) combined with bead beating as previously published. Then the Genomic DNA was sent to the one of the most famous high-throughput sequencing company for high-throughput sequencing and analysis.
The extracted genomic DNA was used as the template to amplify the V3–V4 region of 16S rRNA genes using the primer pair 338F/806R with the barcode. PCR reactions, pyrosequencing of the PCR amplicons and quality control of raw data were performed as described previously with minor modification.
Bioinformatics and Multivariate Statistics
Low-quality sequences were eliminated from analysis based on the following criteria: (a) raw reads shorter than 400 bp; (b) a sequence producing more than eight homopolymers; (c) >2 mismatches in the primers, or, (d) one or more mismatches in the barcode. Pyrosequenced amplicons were removed using the PyroNoise algorithm in Mothur. Bioinformatic analysis was implemented using the Quantitative Insights Into Microbial Ecology (QIIME) platform. Briefly, 16S rRNA operational taxonomic units (OTUs) were clustered using an open-reference OTU picking protocol based on 97% nucleotide similarity with the UCLUST algorithm. ChimeraSlayer was employed to remove chimeric sequences. The relative abundance of each OTU was determined as a proportion of the sum of sequences for each sample. Taxonomic relative abundance profiles (such as, at the phylum, class, order, family, and genus levels) were generated based on OTU annotation. The microbial community structure (i.e., species richness, evenness and between-sample diversity) of bacterial samples was estimated by biodiversity. Shannon index, phylogenetic diversity, Chao1 index, and the observed number of species were used to evaluate alpha diversity, and the weighted and unweighted UniFrac distances were used to evaluate beta diversity.
All of these indices (alpha and beta diversity) were calculated by the QIIME pipeline.
Statistical Analysis
Statistical analysis was implemented using the R platform. Principal coordinate analysis (PCoA) was performed using the “ape” package based on the UniFrac distances between samples. The difference among groups was further assessed using a non-parametric test via Metastats software1 as described previously, and statistical significance was set at p < 0.05 for correction of multiple comparisons.
Sequencing Coverage
To compare the fecal microbes of healthy people (group H) and ALS patients (group A), 16S rRNA amplicon sequencing analysis was used to sequence the V3–V4 hypervariable region, and the sequencing data was filtered to get the valid data, and all the effective tags of all samples were clustered and those sequences with over 97% similarity were considered as one OTU. In total, 802695.96 filtered clean tags (72972.36 tags/sample) and 2540 OTUs were obtained from all the samples with an average of 230.91 OTUs per group (Table 1). Chao1 index had almost got saturated and the rarefaction curve of every sample could enter the plateau phase (Supplementary Figure S1).
Shared Genera in Each Sample
The Venn figure could reflect the difference between group A and group H. As shown in Figure 1, there were 386 and 279 OTUs in group A and H, and the percent of their common OUTs were 63.0% (243/386) and 87.1% (243/279), respectively. For group H, 43.78% OTUs (169/386) were identified as common OUTs among samples H1, H2, H3, H4, and H5, while the common OTUs only occupied 17.56% (49/279) among samples A1, A2, A3, A4, A5, and A6.
The β Diversity of the Microbial Community
The overall picture of the microbial composition of the samples in group A and H was obtained by PCoA, based on the relative abundance profiles of bacterial taxa. As shown in Figure 2, 5/5 samples in group H clustered together on the right upper of the coordinate axis, and 5/6 samples in group A gathered together on the left upper of the coordinate axis, and samples in group H were obviously deviated from the samples in group A (Figure 2A), which was future confirmed by UPGMA method (Figure 2B).
Composition of the Bacterial Communities at Genus Level
At the genus level, data of top 10 microorganism populations was analyzed. As shown in Figure 3, Bacteroides, Faecalibacterium, Anaerostipes, Prevotella, and Escherichia constituted five common dominant genus in group A and H (7.38 vs. 9.41%, 15.32 vs. 7.02%, 23.9 vs. 7.0%, 10.42 vs. 29.86%, 2.57 vs. 3.24%), which accounted for 59.59 and 56.53% of the total sequencing number, and the bacteria did not belong to the dominant bacteria in these two groups and classified as the “others” had occupied 30.77 and 38.29%. In addition, the average ratios of Bacteroides, Faecalibacterium, Anaerostipes, Prevotella, Escherichia, and Lachnospira between groups A and H were 0.78, 2.18, 3.41, 0.35, 0.79, and 13.07 (Figure 3).
Relative Abundance of the Bacterial Communities in Each Sample
To determine the significant increased bacteria in group A or H, supervised comparisons by LEfSE (LDA > 4.0) were performed. In Figure 4, Lachnospiraceae (at family level), Firmicutes (at phylum level), Clostridia (at class level), Oscillibacter (at genus level), Family XIII (at family level), Anaerostipes (at genus level), Lachnospiraceae (at genus level) and Clostridiales (at order level) in group H were significant higher than that in group A, while Bacteroidetes (at phylum level), Bacteroidia (at class level), Bacteroidales (at order level), Dorea (at genus level) were significant higher than that in group H.
Discussion
Accumulating clinical- and scientific research-based evidence is driving our increased awareness of the significance of the human microbiome (HM) to the healthy and homeostatic operation of the human CNS. ALS belongs to neurodegenerative disease characterized by the loss of motor neurons, and the prevalence rate for ALS is substantially lower at 3.9/100000 in the United States. To date, the pathogenesis of ALS remains unclear and is likely multifactorial, and the pathophysiology of ALS may be related to the gastrointestinal tract. The gut microbiota, which is also referred to as the second brain, may affect brain activity through the gut-microbiota–brain axis under both physiological and pathological conditions, and accumulating evidence suggests that microbiota changes in the gastrointestinal tract of individuals possessed strong connection with neurological diseases and specifically, neurodegenerative diseases.
In this study, high-throughput sequencing technology was used to compare the microbiota in intestinal tract of healthy people and ALS patients. To evaluate the tag quality, the raw tags, clean tags, average bp and OTUs in per sample were compared, and the mean number of 72972.36 clean tags, average length of 453 bp (Table 1), and the saturated Chao1 index and rarefaction curve ensured their reliability for the future analysis (Supplementary Figure S1).
In Figure 1, the Venn figure reflected a high percent of 43.78% of common OTUs in H group, and a low percent of 17.56% of common OTUs in A group, which indicated that the ALS, together with individual physiological status, had severely changed the microbial composition in patients feces, which deviating from the normal microbiota and characterized by the overgrowth of total OTU number and low percent of common OTUs. Moreover, the clustered samples A1, A2, A3, A4, and A6, as well as the clustered samples H1, H2, H3, H4, and H5 using PCoA and UPGMA method further conformed the microbial changes in feces of ALS patients (Figure 2).
Then, the top 10 microorganism populations were analyzed at genus level, and average ratios of Bacteroides, Faecalibacterium, Anaerostipes, Prevotella, Escherichia, and Lachnospira between groups A and H were 0.78, 2.18, 3.41, 0.35, 0.79, and 13.07 (Figure 3). Furthermore, supervised comparisons by LEfSE (LDA > 4.0) were performed to find the significant changed bacteria, and the relative richness of Firmicutes at phylum level, Clostridia at class level, Clostridiales at order level, Lachnospiraceae and Family XIII at family level, Oscillibacter, Anaerostipes and Lachnospiraceae at genus level in group H were significant higher than that in group A, while Bacteroidetes at phylum level, Bacteroidia at class level, Bacteroidales at order level and Dorea at genus level were significant higher in group A (Figure 4).
In healthy adults, 80% of the identified fecal microbes can be classified into three dominant phyla: Bacteroidetes, Firmicutes, and Actinobacteria, and the Firmicutes to Bacteroidetes ratio is regarded to be of significant relevance with human health, and the significant increase of Firmicutes in H group and significant increase of Bacteroidetes in A group indicated that the ALS has seriously influenced patients’ healthy, characterized by the decreased Firmicutes/Bacteroidetes ratio. At genus level, the Dorea in group A was significant higher than that in healthy people, whose major end products of glucose metabolism are ethanol. Moreover, the significant decrease of Oscillibacter (was found in significantly more samples from healthy control test subjects than from patients diagnosed with Crohn’s disease; ), Anaerostipes (represents more than 2% of total colonic microbiota in the healthy colon, and are believed to play an important functional role in the gut ecosystem due to their ability to produce butyrate from lactate; ) and Lachnospiraceae (can protect from colon cancer in humans by producing butyric acid; ) in group A further confirmed the interaction of ALS with intestinal microbiota.
In summary, we found that host microbiota were markedly different in health and disease, and the overgrowing of pathogens and reduction of probiotic organisms in intestines of ALS patients might up-regulated or down-regulated the production of NO, GABA, SCFAs, and LPS, which eventually increased the pathogenesis of ALS, and the ALS conversely aggravated the imbalances of intestinal microbiota, causing a vicious circle for host health. In the present study, we provide basic data to clarify the key bacteria during disease occurring, which may assist our understanding and treatment of ALS by inhibiting the growth of pathogens and enhancing the number of probiotics.
Author Contributions
TC designed the experiment; XF, XnW, SY, FM, and XaW performed the experiments; TC and HW analyzed the data and wrote the manuscript. All authors discussed the results and commented on the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References 40
- 1.
- 2.
Barrett E. (2014 ). This article corrects: gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J. Appl. Microbiol. 116 1384–1386.
Not in our library10.1111/j.1365-2672.2012.05344.x
- 3.
Brooks B. R. Miller R. G. Swash M. Munsat T. L. (2000 ). El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Other Motor Neuron Disord. 1 293–299.
Not in our library10.1080/146608200300079536
- 4.
Bui T. P. N. de Vos W. M. Plugge C. M. (2014 ). Anaerostipes rhamnosivorans sp. nov., a human intestinal, butyrate-forming bacterium. Int. J. Syst. Bacteriol. 64 787–793.
Not in our library10.1099/ijs.0.055061-0
- 5.
Cani P. D. Knauf C. (2016 ). How gut microbes talk to organs: the role of endocrine and nervous routes. Mol. Metab. 5 743–752.
Not in our library10.1016/j.molmet.2016.05.011
- 6.
Caporaso J. G. Kuczynski J. Stombaugh J. Bittinger K. Bushman F. D. Costello E. K. (2010 ). QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7 335–336.
Not in our library10.1038/nmeth.f.303
- 7.
Catanzaro R. Anzalone M. Calabrese F. Milazzo M. Capuana M. Italia A. (2015 ). The gut microbiota and its correlations with the central nervous system disorders. Panminerva Med. 57 127–143.
Not in our library
- 8.
Davenport M. Poles J. Leung J. M. Wolff M. J. Abidi W. M. Ullman T. (2014 ). Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm. Bowel Dis. 20 723–731.
Not in our library10.1097/mib.0000000000000011
- 9.
Derrien M. van Hylckama Vlieg J. E. (2015 ). Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 23 354–366.
Not in our library10.1016/j.tim.2015.03.002
- 10.
Erny D. Hrabe de Angelis A. L. Jaitin D. Wieghofer P. Staszewski O. David E. (2015 ). Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18 965–977.
Not in our library10.1038/nn.4030
- 11.
Fang X. (2015 ). Potential role of gut microbiota and tissue barriers in Parkinson’s disease and amyotrophic lateral sclerosis. Int. J. Neurosci. 126 771–776.
Not in our library10.3109/00207454.2015.1096271
- 12.
Gordon P. H. (2011 ). Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs 25 1–15.
Not in our library10.2165/11586000-000000000-00000
- 13.
Grenham S. Clarke G. Cryan J. F. Dinan T. G. (2011 ). Brain-gut-microbe communication in health and disease. Front. Physiol. 2:94
Not in our library10.3389/fphys.2011.00094
- 14.
Haas B. J. Gevers D. Earl A. M. Feldgarden M. Ward D. V. Giannoukos G. (2011 ). Chimeric 16S rRNA sequence formation and detection in sanger and 454-pyrosequenced PCR amplicons. Genome Res. 21 494–504.
Not in our library10.1101/gr.112730.110
- 15.
Hill J. M. Bhattacharjeeand S. Pogue A. I. Lukiw W. J. (2014 ). The gastrointestinal tract microbiome and potential link to Alzheimer’s Disease. Front. Neurol. 5:43
Not in our library10.3389/fneur.2014.00043
- 16.
Kennedy P. Cryan J. Dinan T. Clarke G. (2016 ). Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology. [Epub ahead of print].
Not in our library10.1016/j.neuropharm.2016.07.002
- 17.
Kiernan M. C. Vucic S. Cheah B. C. Turner M. R. Eisen A. Hardiman O. (2011 ). Amyotrophic lateral sclerosis. Lancet 377 942–955.
Not in our library10.1016/s0140-6736(10)61156-7
- 18.
Longstreth W. Meschke J. Davidson S. Smoot L. Smoot J. Koepsell T. (2005 ). Hypothesis: a motor neuron toxin produced by a clostridial species residing in gut causes ALS. Med. Hypotheses 6 1153–1156.
Not in our library10.1016/j.mehy.2004.07.041
- 19.
- 20.
- 21.
Mayer E. A. Tillisch K. Gupta A. (2015 ). Gut/brain axis and the microbiota. J. Clin. Invest. 125 926–938.
Not in our library10.1172/jci76304
- 22.
- 23.
Mehta P. (2015 ). Prevalence of amyotrophic lateral sclerosis-united states, 2010-2011. Am. J. Public Health 105 e7–e9.
Not in our library10.2105/ajph.2015.302747
- 24.
Mondot S. Kang S. Furet J.-P. Aguirre de Cárcer D. McSweeney C. Morrison M. (2011 ). Highlighting new phylogenetic specificities of Crohn’s disease microbiota. Inflamm. Bowel Dis. 17 185–192.
Not in our library10.1002/ibd.21436
- 25.
Nguyen M. D. D’Aigle T. Gowing G. Julien J.-P. Rivest S. (2004 ). Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 24 1340–1349.
Not in our library10.1523/jneurosci.4786-03.2004
- 26.
Rhee S. H. Pothoulakis C. Mayer E. A. (2009 ). Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 6 306–314.
Not in our library10.1038/nrgastro.2009.35
- 27.
Sampson T. R. Mazmanian S. K. (2015 ). Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 17 565–576.
Not in our library10.1016/j.chom.2015.04.011
- 28.
Scarrott J. M. Herranz-Martín S. Alrafiah A. R. Shaw P. J. Azzouz M. (2015 ). Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin. Biol. Ther. 15 935–947.
Not in our library10.1517/14712598.2015.1044894
- 29.
Schloss P. D. Westcott S. L. Ryabin T. Hall J. R. Hartmann M. Hollister E. B. (2009 ). Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75 7537–7541.
Not in our library10.1128/aem.01541-09
- 30.
Serre C. B. D. L. Lartigue G. D. Raybould H. E. (2015 ). Chronic exposure to low dose bacterial lipopolysaccharide inhibits leptin signaling in vagal afferent neurons. Physiol. Behav. 139 188–194.
Not in our library10.1016/j.physbeh.2014.10.032
- 31.
Shokralla S. Spall J. L. Gibson J. F. Hajibabaei M. (2012 ). Next-generation sequencing technologies for environmental DNA research. Mol. Ecol. 21 1794–1805.
Not in our library10.1111/j.1365-294x.2012.05538.x
- 32.
Sivan A. Corrales L. Hubert N. Williams J. B. Aquino-Michaels K. Earley Z. M. (2015 ). Commensal bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 350 1084–1089.
Not in our library10.1126/science.aac4255
- 33.
Vos P. Garrity G. Jones D. Krieg N. R. Ludwig W. Rainey F. A. (2011 ). Bergey’s Manual of Systematic Bacteriology: The Firmicutes, Vol. 3. Berlin: Springer Science & Business Media.
Not in our library
- 34.
Wang H. Lee I.-S. Braun C. Enck P. (2016 ). Effect of probiotics on central nervous system functions in animals and humans–a systematic review. J. Neurogastroenterol. Motil. [Epub ahead of print].
Not in our library10.5056/jnm16018
- 35.
Williams B. Vanbenschoten A. Cimermancic P. Donia M. Zimmermann M. Mao T. (2014 ). Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16 495–503.
Not in our library10.1016/j.chom.2014.09.001
- 36.
Xu J. Lian F. M. Zhao L. H. Zhao Y. F. Chen X. Y. Zhang X. (2015 ). Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. Isme. J. 9 552–562.
Not in our library10.1038/ismej.2014
- 37.
Yu X. Wu X. Qiu L. Wang D. Gan M. Chen X. (2015 ). Analysis of the intestinal microbial community structure of healthy and long-living elderly residents in gaotian village of Liuyang City. Appl. Microbiol. Biotechnol. 99 9085–9095.
Not in our library10.1007/s00253-015-6888-3
- 38.
Yue-Xin M. Holmstrom C. Webb J. (2003 ). Application of denaturing gradient gel electrophoresis (DGGE) in microbial ecology. Acta Ecol. Sin. 8 014.
Not in our library
- 39.
Zhang R. Miller R. G. Gascon R. Champion S. Katz J. Lancero M. (2009 ). Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 206 121–124.
Not in our library10.1016/j.jneuroim.2008.09.017
- 40.
Zhernakova A. Kurilshikov A. Bonder M. J. Tigchelaar E. F. Schirmer M. Vatanen T. (2016 ). Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352 565–569.
Not in our library10.1126/science.aad3369
Cited by papers we hold 8
- Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases · 2024No notice
- Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut–Liver–Brain Axes? · 2023No notice
- Intestinal Microbiota and Sclerosis Lateral Amyotrophic · 2022Not checked
- The Association between Early-Life Gut Microbiota and Long-Term Health and Diseases · 2021No notice
- Fecal Microbiota Transplantation in Neurological Disorders · 2020No notice
- The progress of gut microbiome research related to brain disorders · 2020No notice
- Changes of Colonic Bacterial Composition in Parkinson’s Disease and Other Neurodegenerative Diseases · 2018No notice
- Gut inflammation and dysbiosis in human motor neuron disease · 2017No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.